<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686097</url>
  </required_header>
  <id_info>
    <org_study_id>SAHZhejiangU-003</org_study_id>
    <nct_id>NCT04686097</nct_id>
  </id_info>
  <brief_title>Percutaneous Electrocoagulation Versus Sclerosing Foam for Patients With Incompetent Perforating Veins</brief_title>
  <acronym>PESIV</acronym>
  <official_title>Percutaneous Electrocoagulation Versus Sclerosing Foam for Patients With Incompetent Perforating Veins : A Multi-center Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yantai Yuhuangding Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to compare the efficacy of punctured electrocoagulation and sclerotherapy in&#xD;
      the treatment of incompetent perforator veins.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Incompetent perforating vein (IPV) is one of the important causes of persistent&#xD;
      venous ulcers of lower extremities and recurrence after operation of varices which is a hot&#xD;
      button issue worth discussing in clinical practice. Minimally invasive surgery has become the&#xD;
      trend of IPVs' treatment. Currently, sclerotherapy can be performed to treat incompetent&#xD;
      perforating veins, which showed a 90% occlusion rate after three or fewer sessions, the&#xD;
      recurrence was present nearly 1/3 of cases. While electrocoagulation has a reliable effect on&#xD;
      the closure of incompetent perforating veins and simplify treatment. No comparative studies&#xD;
      of different PAPS modalities are currently available. Therefore, this study aimed to compare&#xD;
      the efficacy of punctured electrocoagulation and sclerotherapy in the treatment of&#xD;
      incompetent perforating veins. Methods:This study is a multicenter, randomized controlled&#xD;
      trial. We will recruit 84 patients with IPVs from five hospitals. Moreover, these patients&#xD;
      will be randomized to either the experimental group (electrocoagulation) or the control group&#xD;
      (sclerotherapy). The primary outcome is incompetent perforating veins occlusion rate in the&#xD;
      12th month. Secondary outcomes are quality of life scale survey results (CEAP classification,&#xD;
      VCSS score, CIVIQ-14 score), skin ulcer recurrence rate, deep venous Thrombosis, hemorrhage,&#xD;
      all-cause mortality, and other vascular events and serious complications.Discussion:This&#xD;
      study will provide reliable, evidence-based clinical evidence for the efficacy of&#xD;
      electrocoagulation therapy for incompetent perforating veins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IPVs occlusion rate in the 12th month.</measure>
    <time_frame>12 months after operation</time_frame>
    <description>IPVs occlusion rate is defined as DS &gt; 50% for each modality with no procedure no procedure performed on the treated segment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale survey results</measure>
    <time_frame>1-month,6-month,12-month</time_frame>
    <description>quality of life scale survey results (CEAP classification, VCSS score, CIVIQ-14 score).Quality of life will be assessed by MOS item short-form health survey scale (SF-36). SF-36 includes eight subscales: physical functioning (PF, 10 items), role limitations due to physical health problems (RL-P, 4 items), bodily pain (BP, 2 items), general health (GH, 5 items), vitality (V, 4 items), social functioning (SF, 2 items), role limitations due to emotional problems (RL-E, 3 items) and mental health (MH, 5 items). The vitality sub-score assesses energy and fatigue, and ranges from 0 (worst) - 100 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin ulcer recurrence rate</measure>
    <time_frame>1-month,6-month,12-month</time_frame>
    <description>Skin ulcer recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with deep venous Thrombosis</measure>
    <time_frame>1-month,6-month,12-month</time_frame>
    <description>deep venous Thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with hemorrhage</measure>
    <time_frame>1-month,6-month,12-month</time_frame>
    <description>Including hemorrhagic stroke, gastrointestinal bleeding, hematuria, mucocutaneous hemorrhage and other visceral bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality and other vascular events and serious complications.</measure>
    <time_frame>1-month,6-month,12-month</time_frame>
    <description>Percentage of participants with all deaths</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Incompetent Perforating Veins</condition>
  <arm_group>
    <arm_group_label>experimental group (electrocoagulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the experimental group will receive ultrasound-guided puncture of coagulation incompetent perforator veins.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group (sclerotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the control group will receive an ultrasound-guided sclerosing agent injected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>treatment: puncture of coagulation</intervention_name>
    <description>ultrasound-guided puncture of coagulation</description>
    <arm_group_label>experimental group (electrocoagulation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>treatment: sclerosing agent injected</intervention_name>
    <description>ultrasound-guided sclerosing agent injected</description>
    <arm_group_label>control group (sclerotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (1) outward flow of less than 500 ms duration, with a diameter of &gt;3.5 mm; (2) According to&#xD;
        the CEAP classification method specified by the International Venous Federation, patients&#xD;
        with C3~C6 grades are included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (1)age &lt; 18 years or age &gt; 80 years; (2)with malignant tumors and life expectancy &lt; 1 year;&#xD;
        (3)with past or current history of deep vein thrombosis and/or pulmonary embolism in the&#xD;
        lower extremities; (4)with congenital venous malformations (K-T syndrome, arteriovenous&#xD;
        fistula and etc.; (5)inability to walk, long-term braking, restrictive bed rest; severe&#xD;
        ischemia of lower extremities or diagnosed severity of peripheral artery occlusive disease;&#xD;
        (6)according to the researcher's judgment, it is not suitable for foam hardener and&#xD;
        puncture coagulation treatment; (7)allergic to the drugs and equipment materials involved&#xD;
        in the research; (8)with inferior vena cava and/or iliac vein stenosis or occlusion;&#xD;
        (9)with autoimmune disease, receiving chemotherapy, hormone therapy or immunomodulatory&#xD;
        treatment; (10)other underlying severe diseases; women who are pregnant, breastfeeding or&#xD;
        have pregnancy plans during the study period; (11)the patient cannot cooperate to complete&#xD;
        the inspection and follow-up required by the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen jie Liu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhen jie Liu</last_name>
    <phone>86-0571-87913706</phone>
    <email>lawson4001@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenjie Liu</last_name>
      <phone>15268135830</phone>
      <phone_ext>86</phone_ext>
      <email>lawson4001@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cooper DG, Hillman-Cooper CS, Barker SG, Hollingsworth SJ. Primary varicose veins: the sapheno-femoral junction, distribution of varicosities and patterns of incompetence. Eur J Vasc Endovasc Surg. 2003 Jan;25(1):53-9.</citation>
    <PMID>12525812</PMID>
  </reference>
  <reference>
    <citation>Sakurai T, Matsushita M, Nishikimi N, Nimura Y. Hemodynamic assessment of femoropopliteal venous reflux in patients with primary varicose veins. J Vasc Surg. 1997 Aug;26(2):260-4.</citation>
    <PMID>9279313</PMID>
  </reference>
  <reference>
    <citation>Guex JJ. Ultrasound guided sclerotherapy (USGS) for perforating veins (PV). Hawaii Med J. 2000 Jun;59(6):261-2.</citation>
    <PMID>10916243</PMID>
  </reference>
  <reference>
    <citation>Masuda EM, Kessler DM, Lurie F, Puggioni A, Kistner RL, Eklof B. The effect of ultrasound-guided sclerotherapy of incompetent perforator veins on venous clinical severity and disability scores. J Vasc Surg. 2006 Mar;43(3):551-6; discussion 556-7.</citation>
    <PMID>16520171</PMID>
  </reference>
  <reference>
    <citation>Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, Lohr JM, McLafferty RB, Meissner MH, Murad MH, Padberg FT, Pappas PJ, Passman MA, Raffetto JD, Vasquez MA, Wakefield TW; Society for Vascular Surgery; American Venous Forum. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011 May;53(5 Suppl):2S-48S. doi: 10.1016/j.jvs.2011.01.079.</citation>
    <PMID>21536172</PMID>
  </reference>
  <reference>
    <citation>Hager ES, Washington C, Steinmetz A, Wu T, Singh M, Dillavou E. Factors that influence perforator vein closure rates using radiofrequency ablation, laser ablation, or foam sclerotherapy. J Vasc Surg Venous Lymphat Disord. 2016 Jan;4(1):51-6. doi: 10.1016/j.jvsv.2015.08.004.</citation>
    <PMID>26946896</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</investigator_affiliation>
    <investigator_full_name>Zhenjie Liu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Perforating veins</keyword>
  <keyword>Venous disease</keyword>
  <keyword>Venous ulcer</keyword>
  <keyword>Sclerotherapy</keyword>
  <keyword>Electrocoagulationt</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosing Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

